MEM-288
AXP000041.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, IFN-beta and chimeric CD40 ligand-armed)
- Originator
- Memgen
- Sponsor
- Memgen
Names
| Name | Type | Source |
|---|---|---|
| MEM-288 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (MEM-288)
- Replication
- conditionally replicating
- Modifications
- armed with IFN-beta and a chimeric membrane-stable CD40 ligand (MEM40)
- Transgenes
- IFNB1, chimeric CD40 ligand (MEM40)
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C185120
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Recruiting | Phase 1 | 2022-04-21 | 2027-02 | 40 | Advanced Cancer; Cutaneous Squamous Cell Carcinoma; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Metastatic Cancer; Non Small Cell Lung Cancer; Pancreatic Cancer; Solid Tumor; Triple Negative Breast Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39276533 | Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer. | Neoplasia (New York, N.Y.) | 2024 | name in title: MEM-288 |
| PMID 36757308 | Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. | Cancer immunology research | 2023 | name in abstract: MEM-288 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA283730 | Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients | H. LEE MOFFITT CANCER CTR & RES INST | BEG, AMER AZIZ | 2024–2026 | name in abstract: MEM-288 |
Notes
Conditionally replicating adenovirus encoding human IFN-beta and a chimeric membrane-stable CD40 ligand (MEM40). Phase I NCT05076760, intratumoral, with nivolumab.
How to cite
MEM-288 (AXP000041.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000041.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.